Holen Sie sich die Stockscreener-App
3.15
1.61%
0.05
Schlusskurs vom Vortag:
$3.10
Offen:
$3.16
24-Stunden-Volumen:
81,111
Relative Volume:
0.89
Marktkapitalisierung:
$7.76M
Einnahmen:
$75,700
Nettoeinkommen (Verlust:
$-7.23M
KGV:
-0.1831
EPS:
-17.2081
Netto-Cashflow:
$-7.37M
1W Leistung:
-1.56%
1M Leistung:
-2.48%
6M Leistung:
-54.31%
1J Leistung:
-58.55%
1-Tages-Spanne:
$3.03
$3.19
1-Wochen-Bereich:
$3.03
$3.35
52-Wochen-Spanne:
$2.3401
$12.03
Aclarion Inc Stock (ACON) Company Profile
Firmenname
Aclarion Inc
Sektor
Branche
Telefon
833 275 2266
Adresse
8181 ARISTA PLACE, BROOMFIELD
Compare ACON vs VEEV, BTSG, TEM, HQY, DOCS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACON
Aclarion Inc
|
3.15 | 7.63M | 75,700 | -7.23M | -7.37M | -17.21 |
VEEV
Veeva Systems Inc
|
159.42 | 26.00B | 3.20B | 908.91M | 1.39B | 5.4168 |
BTSG
Brightspring Health Services Inc
|
55.50 | 10.68B | 13.65B | 169.86M | 412.12M | 1.0758 |
TEM
Tempus Ai Inc
|
46.95 | 8.70B | 1.36B | -302.91M | -219.93M | -1.7182 |
HQY
Healthequity Inc
|
80.46 | 6.90B | 1.31B | 215.20M | 408.32M | 2.4627 |
DOCS
Doximity Inc
|
26.45 | 4.85B | 637.78M | 239.40M | 307.21M | 1.1909 |
Aclarion Inc Aktie (ACON) Neueste Nachrichten
Insider Move: Aclarion Director Makes Bold New Share Purchase - TipRanks
Aclarion director Scott Breidbart acquires $18,011 in stock - Investing.com
Aclarion director Scott Breidbart acquires $18,011 in stock By Investing.com - Investing.com India
Director at Aclarion (ACON) buys 5,664 Common Stock shares in public trade - Stock Titan
Aclarion director David Neal buys $7,750 in company stock By Investing.com - Investing.com Nigeria
Aclarion director David Neal buys $7,750 in company stock - Investing.com
Aclarion (NASDAQ: ACON) director purchases 2,500 shares in open market trade - Stock Titan
TradingKey - TradingKey
Top Executive Makes Bold Insider Move at Aclarion, Inc. - TipRanks
Aclarion (ACON) CEO makes open-market share purchase - Stock Titan
What Aclarion (ACON) is doing that smart money tracks (Momentum Building) 2026-05-08Oversold Bounce - newser.com
Aclarion (ACON) director adds 1,562 shares in open-market purchase - Stock Titan
ACONW (Aclarion WT) quarterly update shows limited financial disclosure as investors await complete earnings details.High Interest Stocks - newser.com
Aclarion adds Lanman Spinal Neurosurgery to CLARITY trial By Investing.com - Investing.com South Africa
Aclarion adds Lanman Spinal Neurosurgery to CLARITY trial - Investing.com
Aclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment - The Manila Times
Beverly Hills spine practice joins 300-patient back pain trial - Stock Titan
Aclarion Announces Addition of First Private Practice Site in Los Angeles Into CLARITY Trial to Further Accelerate Enrollment - 富途牛牛
Aclarion Announces Second Commercial Agreement with Weill Cornell Medicine - Orthopedics This Week
Aclarion Grants Inducement Stock Option to New Western U.S. Commercial Director Amid Growing Demand for Nociscan - citybuzz -
Aclarion Grants Commercial Director Stock Options for 75,000 Shares - geneonline.com
New Western U.S. director gets 17,000-share Aclarion option - Stock Titan
Aclarion Announces Inducement Grant to New Commercial Director, Western U.S. - marketscreener.com
Aclarion establishes second trial agreement with Weill Cornell By Investing.com - Investing.com India
Why Aclarion WT (ACONW) might surprise investors this quarter (Smart Money Exits) 2026-05-05Retail Trader Ideas - newser.com
Aclarion establishes second trial agreement with Weill Cornell - Investing.com
Aclarion announces second commercial agreement with Weill Cornell Medicine - marketscreener.com
Weill Cornell adds Aclarion scan to 2-year spine surgery trial - Stock Titan
What Aclarion (ACON) is doing that smarter investors notice (Slips) 2026-05-05Elite Trading Signals - newser.com
ACONW (Aclarion WT) full quarterly earnings data not yet released, investors await key performance and guidance details.Performance Review - newser.com
Aclarion announces $2.5M stock repurchase plan - MSN
Aclarion reports cash runway to ops into late 2027 - BizWest
Aclarion Reports 196% Annual Scan Volume Growth in Q1 2026, Fueled by Accelerating Clinical Adoption of Nociscan - MEXC Exchange
Aclarion reports 196% jump in Nociscan scan volumes in Q1 - Investing.com UK
Aclarion reports 196% jump in Nociscan scan volumes in Q1 By Investing.com - Investing.com Australia
Aclarion Delivers Strong Q1 2026 Results with 196% Annual Scan Volume Growth Reflecting Accelerating Clinical Adoption - The Manila Times
Back-pain scan use rose 196% as Aclarion funds operations into 2027 - Stock Titan
Aclarion names Daniel Keefe as commercial director for Western US - Medical Buyer
Is Aclarion (ACON) stock suitable for your portfolio? (-3.26%) 2026-04-29High Attention Stocks - newser.com
Recent Insider BuyingStock ScreenerSnapshot - Finviz
Aclarion Appoints Daniel Keefe as Commercial Director, Western U.S., to Drive Continued ... - Bluefield Daily Telegraph
Aclarion, Inc. Appoints Daniel Keefe as Commercial Director, Western U.S - marketscreener.com
Aclarion (NASDAQ: ACON) expands 2022 equity plan in 2026 shareholder proxy - Stock Titan
Finanzdaten der Aclarion Inc-Aktie (ACON)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.05%
2.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):